Description
A kit of 10 vials of Retatrutide. Each vial contains 10mg of lyophilized Retatrutide.
Retatrutide is an investigational once-weekly "triple agonist" that activates GLP-1, GIP, and glucagon receptors. GLP-1 and GIP contribute to appetite suppression and glucose control, while glucagon receptor activity may additionally increase energy expenditure and alter fat metabolism.
The weight-loss results are exceptionally strong. In the Phase 2 obesity trial, the 12 mg dose produced an average weight reduction of 24.2% at 48 weeks, and participants were still losing weight when the trial ended. More recent Phase 3 results have strengthened that finding: in TRIUMPH-1, people taking 12 mg lost an average of 28.3% of body weight at 80 weeks, with 45.3% losing at least 30%. Among participants with a starting BMI of at least 35 who continued to 104 weeks, average weight loss reached 30.3%.
The Phase 3 program has also shown substantial effects in people with type 2 diabetes and established cardiovascular disease. In TRIUMPH-2, participants with type 2 diabetes lost up to 20.8% of body weight at 80 weeks, alongside average HbA1c reductions of up to 1.6 percentage points.





